Day: January 28, 2022

MyChem’s nucleotide synthesis methods are highly complementary to Maravai’s TriLink mRNA technologies Increases capabilities serving the high-growth cell and gene therapy market SAN DIEGO, Jan. 28, 2022 (GLOBE NEWSWIRE) — Maravai LifeSciences, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, announced today that it has acquired MyChem, LLC for $240 million in cash at closing with the potential for additional contingent cash consideration based on achievement of certain conditions after closing. The acquisition will expand Maravai’s product offering of strategic inputs in the rapidly growing markets for therapeutics and vaccine applications. Based in San Diego, California, MyChem is a privately held provider of proprietary, ultra-pure nucleotides to customers in...

Transaction values ETAO International Group (“ETAO”) at a pro forma fully diluted enterprise value of approximately $2.5 billion with existing ETAO shareholders rolling over 100% of their equity into equity of the combined company Transaction expected to provide up to $304 million of cash proceeds, including a fully committed $250 million PIPE at $10 per share and up to $54 million of cash held in the trust account of Mountain Crest Acquisition Corp. III (“Mountain Crest III“) assuming no redemptions by Mountain Crest III shareholders ETAO also received commitments through a separate private placement of $51 million Transaction is expected to close in the summer of 2022, with the combined company expected to trade on the New York Stock Exchange under the symbol “ETAO” NEW YORK and NEW YORK, Jan. 28, 2022 (GLOBE NEWSWIRE) — ETAO...

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1.        KEY INFORMATION(a)   Full name of discloser: CANACCORD GENUITY WEALTH LIMITED(b)   Owner or controller of interests and short positions disclosed, if different from 1(a):        The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. N/A(c)   Name of offeror/offeree in relation to whose relevant securities this form relates:        Use a separate form for each offeror/offeree CLINIGEN GROUP PLC(d)   If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: N/A(e)   Date position held/dealing undertaken:        For...